Lilly to Buy Calytrix Bio for up to $1.5 Billion
The acquisition adds an experimental antibody program for rare blood cancers and could pay Calytrix shareholders up to $1.5 billion.
10 Articles
10 Articles
For the US pharmaceutical company, the purchase is a further step away from the dependence on the business of weight loss.
Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest move in its acquisition spree as it expands into cancer and autoimmune diseases.
Lilly to buy Calytrix Bio for up to $1.5 billion
Nov 16 (Reuters) - Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday. The move is the latest in a string of acquisi...
Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis
/PRNewswire/ -- Calytrix Bio, Inc. ("Calytrix"), a company developing precision, disease-modifying therapies for patients living with myeloproliferative...
The deal is expected to strengthen Lilly's presence in hematology.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium












